434 articles – 313 Notices  [english version]
Fiche concise
In HIV type 1-infected children cytotoxic T lymphocyte responses are associated with greater reduction of viremia under antiretroviral therapy.
Buseyne F., Le Chenadec J., Burgard M., Bellal N., Mayaux M.-J., Rouzioux C., Riviere Y., Blanche S.
AIDS Research and Human Retroviruses 21, 8 (2005) 719-27 - http://hal-pasteur.archives-ouvertes.fr/pasteur-00013704
(16131312)
In HIV type 1-infected children cytotoxic T lymphocyte responses are associated with greater reduction of viremia under antiretroviral therapy.
Florence Buseyne1, Jérôme Le Chenadec2, Marianne Burgard3, Nassima Bellal1, Marie-Jeanne Mayaux2, Christine Rouzioux3, Yves Riviere1, S. Blanche4
1 :  Immunopathologie Virale
CNRS : URA1930 – Institut Pasteur de Paris
25-28 rue du Docteur Roux, F-75724 Paris Cedex 15
France
2 :  Epidémiologie, Démographie et Sciences Sociales: santé reproductive, sexualité et infection à VIH
INSERM : U569 – INED – IFR69 – Université Paris XI - Paris Sud
Secteur Bleu 82, Rue du General Leclerc 94276 LE KREMLIN BICETRE CEDEX
France
3 :  Pharmacologie des antirétroviraux
Université Paris V - Paris Descartes – Hôpital Necker - Enfants Malades
France
4 :  Fédération de Pédiatrie
Hôpital Necker - Enfants Malades
Centre Hospitalo-Universitaire Necker-Enfants Malades, Paris, France
France
The evolution of the HIV-specific CD8+ T cell response in patients receiving potent combination therapy has been well documented in adult patients. However, no study reported whether baseline HIV-specific CD8+ T cell response is linked to treatment outcome. The aims of this study were to investigate both the impact of baseline memory cytotoxic T lymphocytes (CTL) on treatment outcome and the effect of potent therapy on memory HIV-specific CTL in HIV-1-infected pediatric patients. The study group comprised 30 children who started a first-line combination treatment including at least three drugs from two different classes and were longitudinally followed during treatment. Their memory HIV-specific responses were measured at baseline and during treatment, as well as their plasma viremia and CD4+ levels. The intensity of memory Gag-specific CTL and the breadth of the CTL response at the beginning of treatment were significantly correlated with lower plasma viral load during treatment, independently of baseline plasma viral load, CD4+ counts, and age. Children with partially controlled viral replication had enhanced Gag-specific CTL compared to their baseline value. This improvement of antiviral responses during treatment was not observed when viral replication was either fully suppressed or uncontrolled. In conclusion, our results show that higher baseline HIV-specific CTL are linked to lower viremia under combination therapy. This result adds further support to the hypothesis that cooperation between the antiviral immune response and antiviral drugs could be helpful for therapeutic management of HIV-infected patients.
Anglais
0889-2229

Articles dans des revues avec comité de lecture
10.1089/aid.2005.21.719
AIDS Research and Human Retroviruses (AIDS Res Hum Retroviruses)
Publisher Mary Ann Liebert
ISSN 0889-2229 (eISSN : 0889-2229)
non spécifiée
08/2005
21
8
719-27

Acquired Immunodeficiency Syndrome – Adolescent – Anti-HIV Agents – CD4 Lymphocyte Count – Child – Preschool – Cross-Sectional Studies – Drug Therapy – Combination – HIV-1 – Humans – Infant – Longitudinal Studies – T-Lymphocytes – Cytotoxic – Viral Load – Viremia